|  |  |  |  |
| --- | --- | --- | --- |
| Biotin | | | |
| Preparations listed in the Drug tariff | [**Part VIIIA (hover the mouse here for more info):**](#PartVIIIA) | | **DT price** |
| None | |  |
| [**Part VIIIB (hover the mouse here for more info):**](#PartVIIIB) | | **DT price** |
| None | |  |
| Administration in swallowing difficulties | | | |
| Tablets may be crushed and mixed with food or drink1.  Tablets can be crushed and mixed with a small amount of soft food such as yoghurt, honey or mashed potato2. | | | |
| Administration in enteral feeding tube | | | |
| No information | | | |
| Comments | | | |
| Biotin is indicated in neonates and children for isolated carboxylase defects and defects of biotin metabolism1.  There are no UK licensed biotin medicines available. BiotEss 5mg tablet (£13.81 for 30) is an unlicensed brand, however this is listed in the Dictionary of medicines and devices which gives an indicative price maintained by the NHSBSA3. It is the most cost-effective brand available.  Biotin is NHSE commissioned for multiple sclerosis4 (Hospital only) | | | |
| References   1. BNFC last updated 8 May 2019 <https://bnfc.nice.org.uk/> date accessed 6 June 2019 2. Biotin for metabolic disorders leaflet information. Medicines for Children. Published 13/11/2013. Version 1, August 2013 <https://www.medicinesforchildren.org.uk/biotin-metabolic-disorders-0> date accessed 6 June 2019 3. NHSBSA Dictionary of medicines and devices (dm+d) BiotEss 5mg tablets (30) price last updated 26/3/2019 <https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/dictionary-medicines-and-devices-dmd> date accessed 6 June 2019 4. NHS England Drugs list version 14 <https://www.england.nhs.uk/publication/nhs-england-drugs-list/> date accessed 6 June 2019 5. Drug Tariff June 2019 <https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff> date accessed 13 June 2019 | | | |
| **Please note: full instructions should be provided to the person administering the medicine. This is guidance only and should not determine individualised care.** | | | |
| Author: Vicki Kong, QIPP Programme Pharmacist, BHR CCGs  Approved by BHR CCGs Area Prescribing sub-Committees: July 2019 | | | |
| Review date: July 2021 | | Version: 1 | |